麻豆传媒

Meeting Coverage >

ACR

For Better COVID Vax Response in Rheumatology Patients, Hold the MMF Longer

Small study suggests at least a 10-day holiday

Another Adalimumab Biosimilar Seems Set for Interchangeability

Trial data pave way for FDA approval

Safer Alternative to Cyclophosphamide at Hand for ILD?

Drug targeting B cells as effective as broad-spectrum immunosuppressant in lung disease

Novel BTK Inhibitor Looks Good for Sjogren's Syndrome

Phase II data show good efficacy by objective measures, even with strong placebo effect

ANCA-Associated Vasculitis: Novel Biologic Shows Promise for Replacing Steroids

Small trial demonstrates big cut in steroid-linked adverse effects

Twelve-Month Data Back Pegloticase-Methotrexate Gout Combo

More support for add-on methotrexate to maintain protein drug's efficacy

Want a Few Weeks of Knee Pain Relief? Try This

Local nerve block proves mettle in randomized trial, though benefit didn't last long

For Systemic JIA, Start Biologics Early

Observational study shows excellent efficacy in systemic pediatric arthritis

Secukinumab: An Up-and-Coming Option in Giant Cell Arteritis?

Phase II trial found sustained remission with steroid-sparing effects

Voclosporin Benefits in Nephritis Persist at 30 Months

No new safety signals seen in long-term extension for lupus nephritis

Vitamin D and Disease Prevention: Worth Another Look?

Incidence of autoimmune disease decreased by 25-30% with dietary supplements

Guselkumab Response Durable in Psoriatic Arthritis

Skin and joint improvements persisted through 2 years of follow-up

Early Biologics Better in Juvenile Idiopathic Arthritis

After 2 years, more patients on combo biologic/DMARD regimen had inactive disease

Brepocitinib Shows Promise in Phase II Trial for PsA

Oral tyrosine kinase 2/JAK-1 inhibitor improved both joint and skin manifestations

Targeting IL-23 Succeeds in Psoriatic Arthritis

Patients had active, longstanding disease and inadequate responses to other agents

Can Abatacept Reverse Early Rheumatoid Arthritis?

At-risk patients showed improvements in inflammation -- and also delays in disease onset

TYK2 Inhibition Promising in Psoriatic Arthritis

Phase II study found significant benefits for two doses of novel agent

High B-Cell Depletion Succeeds in Lupus Nephritis

Obinutuzumab was more effective at depleting B cells than rituximab

COVID Complications Common with Rheumatic Disease

Adverse outcomes included acute kidney injury and congestive heart failure

Rinvoq for RA: Benefits Persist Beyond 1 Year

Manufacturer's extension study shows no loss of clinical response

ACR: Treat-to-Target Endorsed for Gout

Differs from ACP guideline for primary care: "they're wrong"

ACR: Draft OA Guidelines Stress Non-Drug Tx, Leave Opioid Door Open

But group comes down hard on stem cells, PRP, electrical therapy; downgrades hyaluronic acid shots

Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy

Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them

Reassurance on Live-Virus Shingles Vax With Anti-TNFs

Randomized trial indicates fears of infection unfounded

BTK Inhibitor Passes Phase II Test in RA

Novel mechanism for a rheumatoid arthritis drug

Abuse in Many Fibromyalgia Patients' Past

And tied to more severe symptoms

ACR: Can Tanezumab Be Revived for OA?

Low incidence of rapidly progressive OA seen with lower doses

In Psoriatic Arthritis, Doubling Down on IL-17

Bimekizumab targets both IL-17A and F; "astonishing" results in psoriatic arthritis

Treat-to-Target Strategy Cuts Mortality in Gout Patients

Study sets serum urate therapeutic level

ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE

Responses were sustained out to 1 year with ustekinumab

Childhood Trauma: Risk Factor for Lupus in Adulthood?

Nurses Health Study data show a link

RA Guideline Adherence Spotty, Study Finds

Treat-to-target recommendation not followed for half of patients

Recurrent Post-Transplant Lupus Nephritis Declining

Single-center study credits improvements in immunosuppression

Is JAK Inhibition the Next Big Thing in PsA?

Proof-of-concept study suggests a potential role for oral filgotinib

New JAK1 Agent Beats Humira in Rheumatoid Arthritis

Thrombotic events balanced between upadacitinib, adalimumab, and placebo

Can Imaging Replace Biopsy for GCA Diagnosis?

Ultrasound, PET/CT may offer advantages

Selective IL-23 Inhibitor Shines in Mid-Stage PsA Trial

Risankizumab broadly effective against joint and skin symptoms

PsA Structural Damage Inhibited with Secukinumab

Loading dose appears to improve outcomes, researchers say

Novel Drug Promising for IgG4-Related Disease

8 of 15 patients achieved remission in phase II study

Prospects Good for Ustekinumab Gaining SLE Indication

Positive phase II data reported in ACR late-breaker

1